Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) ...

Patient-centered education and navigation support increase consent rates for genomic testing, aiding integration into cancer care and access to genomics-based trials. The SURGE study underscores the ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...

The American College of Medical Genetics and Genomics (ACMG) has published a new clinical practice resource, “Management of Individuals with Heterozygous Germline Pathogenic Variants in RAD51C, RAD51D ...

Salivary gland cancers (SGCs) are rare and comprise multiple histologic entities. In the recurrent or metastatic (R/M) setting, there is limited evidence for effective systemic anticancer treatment ...

Multigene NGS on tumor tissue accurately identifies pathogenic variants in EOC, supporting a tumor-first genetic testing model. The study found 94.3% of tumors had detectable variants, with 99.1% ...

Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH (HGNC:3700). This paper quantitatively weights ...

Genetic testing is rapidly moving genomics from a niche specialty to becoming more integrated into mainstream clinical practice. Once deployed primarily to diagnose rare and inherited conditions after ...

Guidelines recommend offering germline testing to patients with advanced prostate cancer (PCa) to inform treatment and personal/familial cancer risk. We asked whether veterans affairs (VA) patients ...